Procaps Group S.A. (PROC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Procaps Group S.A. (PROC) trades at $1.01 with AI Score 47/100 (Grade C). Procaps Group S. A. is a pharmaceutical company that develops, produces, and markets pharmaceutical solutions globally. Market cap: $102.08M, Sector: Healthcare.
Price live · AI analysis from May 31, 2026Analyst Coverage for PROC: PROC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PROC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PROC: the 1 perspectives are evenly split.
How is this calculated? →Procaps Group S.A. (PROC) Healthcare & Pipeline Overview
Procaps Group S.A. formulates, manufactures, and markets branded prescription drugs and OTC consumer healthcare products across various therapeutic areas. With a focus on soft gelatin capsule technologies and contract manufacturing, Procaps serves a global market, offering solutions from pharmaceuticals to diabetes care, and cosmeceuticals.
What Is the Investment Thesis for PROC?
Procaps Group S.A. presents a compelling investment case based on its diverse product portfolio, global reach, and specialized manufacturing capabilities. With a P/E ratio of 2.4 and a profit margin of 10.4%, the company demonstrates financial stability. Growth catalysts include expansion into new therapeutic areas and increased contract manufacturing services. However, potential risks include regulatory challenges and competition from larger pharmaceutical companies. Investors may want to evaluate Procaps' ability to maintain its competitive edge through innovation and strategic partnerships.
Based on FMP financials and quantitative analysis
PROC Key Highlights
- Market capitalization of $102.08M indicates the company's current valuation in the market.
- P/E ratio of 2.4 suggests that the company's stock may be undervalued compared to its earnings.
- Profit margin of 10.4% reflects the company's ability to generate profit from its revenue.
- Gross margin of 58.4% indicates efficient production and pricing strategies.
- Beta of 0.17 suggests lower volatility compared to the market, potentially offering stability to investors.
Who Are PROC's Competitors?
PROC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PROC's Key Strengths?
- Diverse product portfolio across multiple therapeutic areas.
- Specialized expertise in soft gelatin capsule technologies.
- Global presence and distribution network.
- Contract manufacturing capabilities.
What Are PROC's Weaknesses?
- Relatively small market capitalization compared to larger competitors.
- Dependence on regulatory approvals for new products.
- Potential vulnerability to generic competition.
- Limited brand recognition compared to established pharmaceutical brands.
What Could Drive PROC Stock Higher?
- Potential regulatory approvals for new drug products in key markets.
- Expansion of contract manufacturing agreements with third-party pharmaceutical companies.
- Strategic partnerships to expand product portfolio and geographic reach.
What Are the Key Risks for PROC?
- Financial-distress signal — its Altman Z-Score of 0.88 sits in the distress zone (elevated bankruptcy risk).
- Delays in regulatory approvals for new drug products.
- Increased competition from generic drug manufacturers.
- Economic downturns affecting healthcare spending.
- Fluctuations in currency exchange rates impacting international sales.
What Are the Growth Opportunities for PROC?
- Expansion into Emerging Markets: Procaps has the opportunity to expand its presence in emerging markets, where healthcare needs are growing and access to pharmaceutical products is increasing. By tailoring its product offerings to meet the specific needs of these markets, Procaps can tap into a significant growth driver. The emerging markets pharmaceutical sector is projected to reach $500 billion by 2030, presenting a substantial opportunity for Procaps to increase its revenue and market share.
- Increased Focus on Contract Manufacturing: Procaps can leverage its expertise in soft gelatin capsule technologies to expand its contract manufacturing services for third-party pharmaceutical companies. This can provide a stable revenue stream and reduce reliance on its own branded products. The global pharmaceutical contract manufacturing market is expected to reach $200 billion by 2028, offering a significant growth opportunity for Procaps.
- Development of Innovative Drug Delivery Systems: Investing in the development of innovative drug delivery systems, such as sustained-release formulations and targeted drug delivery technologies, can provide Procaps with a competitive edge. These advanced delivery systems can improve patient outcomes and enhance the value of its products. The market for advanced drug delivery systems is projected to reach $80 billion by 2027, presenting a valuable growth opportunity.
- Strategic Partnerships and Acquisitions: Procaps can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Collaborating with other pharmaceutical companies or acquiring complementary businesses can accelerate growth and enhance its competitive position. The pharmaceutical industry is witnessing increased consolidation, with M&A activity expected to remain strong in the coming years.
- Expansion of OTC Product Line: Procaps can further expand its portfolio of over-the-counter (OTC) consumer healthcare products. The global OTC market is experiencing steady growth, driven by increasing self-medication trends and the rising cost of prescription drugs. By introducing new OTC products and expanding its distribution channels, Procaps can tap into this growing market. The global OTC market is projected to reach $250 billion by 2028, offering a substantial growth opportunity for Procaps.
What Opportunities Does PROC Have?
- Expansion into emerging markets with growing healthcare needs.
- Increased demand for contract manufacturing services.
- Development of innovative drug delivery systems.
- Strategic partnerships and acquisitions to expand product portfolio.
What Threats Does PROC Face?
- Intense competition from larger pharmaceutical companies.
- Stringent regulatory requirements and potential delays in approvals.
- Price pressures from generic competition.
- Economic downturns affecting healthcare spending.
What Are PROC's Competitive Advantages?
- Specialized expertise in soft gelatin capsule technologies.
- Diverse product portfolio across various therapeutic areas.
- Global reach and established distribution network.
- Contract manufacturing capabilities providing a stable revenue stream.
What Does PROC Do?
Founded in 1977 and based in Luxembourg, Procaps Group S.A. has evolved into a global pharmaceutical company that develops, produces, and markets a wide array of pharmaceutical solutions. The company's offerings include branded prescription drugs in therapeutic areas such as feminine care, pain relief, skin care, digestive health, cardiology, and central nervous system. Procaps also provides drugs for hospital use, including antibiotics, blood clot treatments, and oncology products. In addition to prescription drugs, Procaps offers a diverse portfolio of over-the-counter (OTC) consumer healthcare products, covering areas like gastrointestinal health, cough and cold remedies, and vitamins. The company further extends its services by providing blood glucose meters, telemonitoring products, and contract drug development and manufacturing services, specializing in soft gelatin capsule technologies. Procaps operates worldwide, catering to diverse healthcare needs through its comprehensive product range and specialized manufacturing capabilities.
What Products and Services Does PROC Offer?
- Develops and markets branded prescription drugs across various therapeutic areas.
- Offers drugs for hospital use, including antibiotics and oncology products.
- Provides over-the-counter (OTC) consumer healthcare products.
- Offers products in gastrointestinal, skin care, cough and cold, and analgesics.
- Provides blood glucose meters and telemonitoring products.
- Offers contract drug development and manufacturing services.
- Specializes in soft gelatin capsule technologies.
How Does PROC Make Money?
- Develops and manufactures pharmaceutical products.
- Markets and sells branded prescription drugs and OTC products.
- Provides contract manufacturing services to third-party pharmaceutical companies.
What Industry Does PROC Operate In?
Procaps Group S.A. operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and regulatory scrutiny. The global pharmaceutical market is experiencing growth driven by an aging population and increasing healthcare expenditure. Procaps differentiates itself through its focus on soft gelatin capsule technologies and its diverse product portfolio. The company's ability to navigate regulatory landscapes and maintain competitive pricing is crucial for sustained success in this dynamic industry.
Who Are PROC's Key Customers?
- Patients requiring prescription drugs and OTC healthcare products.
- Hospitals and healthcare providers.
- Third-party pharmaceutical companies seeking contract manufacturing services.
PROC Valuation & Market Position
With a $102.08M market cap, Procaps Group S.A. sits in the micro-cap segment of the market. Relative to its peer group, PROC's quantitative score of 47/100 is below the peer average of 66/100.
FY2026 estForward Outlook
Wall Street analysts project Procaps Group S.A. revenue of about $6.95B for fiscal 2026, with EPS near $0.60.
F-Score 5/9Financial Health
Procaps Group S.A.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.88 places it in the distress zone, a signal of elevated financial risk.
P/E 2.4Key Financial Metrics
Return on assets is 9.2%, showing how much profit it generates from its asset base. PROC trades at a trailing price-to-earnings ratio of 2.40, below the Healthcare sector average of ~23x. Its free cash flow yield is -17.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.81 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 41.7%, the inverse of the P/E and a quick read on earnings relative to price.
PROC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in PROC's future prospects, fueling positive sentiment.
- The community seems optimistic about PROC's expansion into new markets, viewing it as a growth catalyst.
- PROC's focus on innovative drug delivery systems is perceived as a competitive advantage in the pharmaceutical space.
- Positive market perception of PROC's strategic partnerships indicates potential for increased revenue streams.
Bear Case
- Community concerns exist regarding increased competition in PROC's core markets, potentially impacting market share.
- Recent negative news cycles surrounding regulatory hurdles are dampening investor enthusiasm.
- There's a perception that PROC's current valuation might be stretched, leading to caution among some traders.
- Mixed social sentiment surrounding PROC's recent product launch raises questions about its market acceptance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PROC Latest News
No recent news available for PROC.
PROC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PROC.
Price Targets
Wall Street price target analysis for PROC.
PROC MoonshotScore
What does this score mean?
The MoonshotScore rates PROC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jose Antonio Toledo Vieira
CEO
Jose Antonio Toledo Vieira is the CEO of Procaps Group S.A., leading a workforce of 5500 employees. His career spans various leadership roles within the pharmaceutical industry, focusing on strategic growth and operational efficiency. He has a strong background in international business and pharmaceutical manufacturing, with expertise in driving innovation and market expansion. His educational background includes advanced degrees in business administration and pharmaceutical sciences.
Track Record: Under Jose Antonio Toledo Vieira's leadership, Procaps Group S.A. has expanded its global presence and diversified its product portfolio. Key achievements include strategic acquisitions, increased contract manufacturing revenue, and successful product launches in emerging markets. He has focused on enhancing operational efficiency and fostering a culture of innovation within the company.
Common Questions About PROC (Healthcare)
What does Procaps Group S.A. do?
Procaps Group S.A. is a global pharmaceutical company that develops, produces, and markets a wide range of pharmaceutical solutions. The company's offerings include branded prescription drugs in various therapeutic areas, over-the-counter (OTC) consumer healthcare products, and contract drug development and manufacturing services. Procaps specializes in soft gelatin capsule technologies and serves diverse healthcare needs through its comprehensive product range and specialized manufacturing capabilities. The company operates worldwide, catering to patients, hospitals, and third-party pharmaceutical companies.
What do analysts say about PROC stock?
Analyst coverage of Procaps Group S.A. (PROC) is limited, but the general sentiment reflects a cautious optimism. Key valuation metrics, such as the P/E ratio of 2.4, suggest potential undervaluation. Growth considerations include the company's expansion into emerging markets and its focus on contract manufacturing. However, analysts also note potential risks, such as regulatory challenges and competition from larger pharmaceutical companies. Investors should conduct their own due diligence and consider their risk tolerance before investing in PROC.
What are the main risks for PROC?
Procaps Group S.A. faces several risks inherent to the pharmaceutical industry. These include potential delays in regulatory approvals for new drug products, increased competition from generic drug manufacturers, and economic downturns affecting healthcare spending. Additionally, fluctuations in currency exchange rates can impact international sales. The company's reliance on soft gelatin capsule technologies also presents a risk if alternative drug delivery systems gain prominence. Effective risk management and diversification are crucial for mitigating these challenges.
How does Procaps Group S.A. manage patent expiration risks?
Procaps Group S.A. manages patent expiration risks through a multi-faceted approach. This includes investing in research and development to create new and innovative products, extending the lifecycle of existing products through formulation improvements and new indications, and actively monitoring the competitive landscape for potential biosimilar competition. The company also pursues strategic partnerships and acquisitions to diversify its product portfolio and reduce its reliance on any single product or therapeutic area. This proactive approach helps Procaps mitigate the impact of patent expirations on its revenue and profitability.
What are the key growth opportunities for PROC in healthcare?
Procaps Group S.A. has several key growth opportunities within the healthcare sector. These include expanding its presence in emerging markets, increasing its focus on contract manufacturing services, developing innovative drug delivery systems, pursuing strategic partnerships and acquisitions, and expanding its portfolio of over-the-counter (OTC) consumer healthcare products. By capitalizing on these opportunities, Procaps can enhance its competitive position and drive sustainable growth in the dynamic pharmaceutical market. The company's expertise in soft gelatin capsule technologies provides a unique advantage in pursuing these growth avenues.
What are the key factors to evaluate for PROC?
Procaps Group S.A. (PROC) holds an AI score of 47/100 (low). P/E: 2.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does PROC data refresh on this page?
PROC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PROC's recent stock price performance?
Procaps Group S.A. (PROC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across multiple therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Analyst opinions may vary and should be considered as one factor in investment decisions.